[1] 魏凡,彭立,谢青. 糖尿病早期视网膜神经变性研究新进展[J]. 国际眼科杂志,2025,25(1):76-81. DOI:10.3980/j.issn.1672-5123.2025.1.14.
[2] Guo Y, Sun Z, Wang L, et al. Increased expression of TSPO-VDAC complex is correlated with NLRP3 inflammasome activation in diabetic retinopathy[J]. Mol Med Rep, 2022,26(6):353. DOI: 10.3892/mmr.2022.12869.
[3] Kuo CYJ, Murphy R, Rupenthal ID, et al. Correlation between the progression of diabetic retinopathy and inflammasome biomarkers in vitreous and serum - a systematic review[J]. BMC Ophthalmol, 2022, 22(1):238. DOI: 10.1186/s12886-022-02439-2.
[4] You H, Li H, Gou W. lncRNA HOTAIR promotes ROS generation and NLRP3 inflammasome activation by inhibiting Nrf2 in diabetic retinopathy[J]. Medicine (Baltimore), 2023, 102(37):e35155. DOI: 10.1097/MD.0000000000035155.
[5] Sun KX, Chen YY, Li Z, et al. Genipin relieves diabetic retinopathy by down-regulation of advanced glycation end products via the mitochondrial metabolism related signaling pathway[J]. World J Diabetes, 2023, 14(9):1349-1368. DOI: 10.4239/wjd.v14.i9.1349.
[6] Zheng X, Wang M, Liu S, et al. A lncRNA-encoded mitochondrial micropeptide exacerbates microglia-mediated neuroinflammation in retinal ischemia/reperfusion injury[J]. Cell Death Dis, 2023, 14(2):126. DOI: 10.1038/s41419-023-05617-2.
[7] Ramezani A, Pardis M, Rafati N, et al. Causes of visual impairment among patients referred to a visual rehabilitation clinic in Iran[J]. Korean J Ophthalmol, 2012, 26(2):80-3. DOI: 10.3341/kjo.2012.26.2.80.
[8] 唐德荣,杨雨雯,石蕊,等. 糖尿病视网膜神经损伤的病变规律及危险因素分析[J]. 眼科新进展,2023,43(12):964-969. DOI:10.13389/j.cnki.rao.2023.0191.
[9] 吴丹萍,王雪,廖宇洁,等. 早期糖尿病视网膜病变患者黄斑神经节细胞层厚度及视盘参数的变化[J]. 国际眼科杂志,2023,23(7):1168-1172. DOI:10.3980/j.issn.1672-5123.2023.7.21.
[10] 中华医学会眼科学会眼底病学组. 我国糖尿病视网膜病变临床诊疗指南(2014年)[J]. 中华眼科杂志,2014,50(11):851-865. DOI:10.3760/cma.j.issn.0412-4081.2014.11.014.
[11] 朱鸿静,张薇玮,张雅纹,等. 重度非增生型糖尿病视网膜病变患眼黄斑区及视盘血流密度和中心凹无血管区面积观察[J]. 中华眼底病杂志,2021,37(2):98-103. DOI:10.3760/cma.j.cn511434-20200518-00220.
[12] 马威奇,黎华源,朱淑婷,等. 2型糖尿病早期视网膜神经厚度检测与并发症相关因素分析[J]. 广东医学,2021,42(5):562-568. DOI:10.13820/j.cnki.gdyx.20202629.
[13] 余海跃,滕娟,朱光.定量分析糖尿病视网膜病变患者视盘周围视网膜和脉络膜血流灌注[J].眼科新进展,2023,43(1):44-46.DOI:10.13389/j.cnki.rao.2023.0009.
[14] 李晓晖,田莲姬,史静云,等. NLRP3炎症小体信号通路在视网膜疾病发生发展中的作用[J]. 国际眼科杂志,2024,24(6):902-905. DOI:10.3980/j.issn.1672-5123.2024.6.12.
[15] Li N, Guo XL, Xu M, et al. Network pharmacology mechanism of Scutellarin to inhibit RGC pyroptosis in diabetic retinopathy[J]. Sci Rep, 2023, 13(1):6504. DOI: 10.1038/s41598-023-33665-3.
[16] Cliff CL, Squires PE, Hills CE. Tonabersat suppresses priming/activation of the NOD-like receptor protein-3 (NLRP3) inflammasome and decreases renal tubular epithelial-to-macrophage crosstalk in a model of diabetic kidney disease[J]. Cell Commun Signal, 2024, 22(1):351. DOI: 10.1186/s12964-024-01728-1.
[17] Chen Y, Yao G, Tong J, et al. MSC-derived small extracellular vesicles alleviate diabetic retinopathy by delivering miR-22-3p to inhibit NLRP3 inflammasome activation[J]. Stem Cells, 2024, 42(1):64-75. DOI: 10.1093/stmcls/sxad078.
[18] Zhang LC, Li N, Xu M, et al. Salidroside protects RGC from pyroptosis in diabetes-induced retinopathy associated with NLRP3, NFEZL2 and NGKB1, revealed by network pharmacology analysis and experimental validation[J]. Eur J Med Res, 2024, 29(1):60. DOI: 10.1186/s40001-023-01578-6.
[19] Zhao H, Liu H, Yang Y, et al. The role of H2S regulating NLRP3 inflammasome in diabetes[J]. Int J Mol Sci, 2022, 23(9):4818. DOI: 10.3390/ijms23094818.
[20] Raman KS, Matsubara JA. Dysregulation of the NLRP3 inflammasome in diabetic retinopathy and potential therapeutic targets[J]. Ocul Immunol Inflamm, 2022, 30(2):470-478. DOI: 10.1080/09273948.2020.1811350.
[21] Kuo CY, Maran JJ, Jamieson EG, et al. Characterization of NLRP3 inflammasome activation in the onset of diabetic retinopathy[J]. Int J Mol Sci, 2022, 23(22):14471. DOI: 10.3390/ijms232214471.
[22] 张志诚,王斌,罗征键,等. 糖尿病视网膜病变患者血清miR-20b-3p、miR-192表达与NLRP3炎症小体和预后不良的关系[J]. 四川医学,2024,45(8):863-869. DOI:10.16252/j.cnki.issn1004-0501-2024.08.010.
[23] 周琦,吕红彬,王亚平,等. NLRP3炎症小体在糖尿病视网膜病变神经血管单元损伤中的机制研究[J]. 国际眼科杂志,2023,23(8):1317-1322. DOI:10.3980/j.issn.1672-5123.2023.8.15.
[24] Lepre CC, Russo M, Trotta MC, et al. Inhibition of galectins and the P2X7 purinergic receptor as a therapeutic approach in the neurovascular inflammation of diabetic retinopathy[J]. Int J Mol Sci, 2023, 24(11):9721. DOI: 10.3390/ijms24119721.
[25] 杨可来尔,匡洪宇. 糖尿病视网膜病变与NLRP3炎性小体[J]. 国际内分泌代谢杂志,2023,43(2):136-139. DOI:10.3760/cma.j.cn121383-20211214-12033.
[26] Mohammad HMF, Eladl MA, Abdelmaogood AKK, et al. Protective effect of topiramate against diabetic retinopathy and computational approach recognizing the role of NLRP3/IL-1β/TNF-α signaling[J]. Biomedicines, 2023, 11(12):3202. DOI: 10.3390/biomedicines11123202.
[27] 尹晓艳,董永孝,刘彦章,等. 舒洛地特通过调节NLRP3表达对视网膜Müller细胞凋亡的影响[J]. 临床和实验医学杂志,2022,21(10):1013-1017. DOI:10.3969/j.issn.1671-4695.2022.10.002.
[28] Ikeda T, Nakamura K, Kida T, et al. Possible roles of anti-type II collagen antibody and innate immunity in the development and progression of diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2022, 260(2):387-403. DOI: 10.1007/s00417-021-05342-6.
[29] Yang L, Li Z, Fang J. Scutellarin alleviates diabetic retinopathy via the suppression of nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing protein 3 inflammasome activation[J]. Curr Eye Res, 2024,49(2):180-187. DOI: 10.1080/02713683.2023.2273777.
[30] Kong H, Zhao H, Chen T, et al. Correction: targeted P2X7/NLRP3 signaling pathway against inflammation, apoptosis, and pyroptosis of retinal endothelial cells in diabetic retinopathy[J]. Cell Death Dis, 2025, 16(1):389. DOI: 10.1038/s41419-025-07682-1.
[31] 冯梅,江霞,王艳丽,等. 富氢水对糖尿病视网膜病变大鼠硫氧还蛋白相互作用蛋白/核苷酸结合寡聚化结构域样受体蛋白3通路及视网膜血管通透性的影响[J]. 安徽医药,2022,26(7):1367-1373,前插2. DOI:10.3969/j.issn.1009-6469.2022.07.022.
|